SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.


Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.


Already have an account? Log in here

ARCE Tx to Advance ARD103 into the Clinic after Promising Preclinical Results in AML; NKGen Biotech and Affimed not Proceeding to Ph2 Trial Combining AFM24 and SNK01 in Solid Tumors; ASCO Breakthrough 2023 Analysis

Here is a brief preview of this blast: ASCO Breakthrough 2023 Analysis: ARCE Tx reported preclinical updates from ARD103, a CLL-1 CAR-T manufactured with its DashCAR technology, while NKGen biotech and Affimed presented initial results of their collaboration to evaluate SNK01 (autologous NK cells) in combination with AFM24 (EGFR x CD16 bispecific NK cell engager) in advanced or metastatic EGFR+ solid tumors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.